Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Q1 FY2023-24 Earnings Call21-07-2023
21-07-2023
Q1FY24 Quarterly Result Announced for Glenmark Life Sciences Ltd.
Pharmaceuticals company Glenmark Life Sciences announced Q1FY24 results: GLS registered revenue from operations of Rs 5,785 million for Q1FY24, recording a strong growth of 18.1% YoY and a decline of 6.9% compared to the high base of Q4FY23. Gross margins improved strongly in Q1FY24 trending at 57.1%, up 220 bps QoQ and 380 bps YoY; driven by lower input costs and a better product mix. EBITDA for Q1FY24 was at Rs 1,950 million up 24.8% YoY. EBITDA margins were at 33.7%, up 180 bps YoY driven by higher gross margin and offset by higher operating cost. PAT was at Rs 1,355 million in Q1FY24, registering a growth of 24.6% YoY. PAT Margin for the quarter was at 23.4%, up 120 bps YoY. R&D; expenditure for Q1FY24 was at Rs 174 million, 3% of sales. Capital expenditure for Q1FY24 was at Rs 354 million. ROICE (adjusted for Cash and CWIP) was 35% for Q1FY24 and the Fixed assets turnover ratio at 2.7x. Strong free cash generation of Rs 982 million during Q1FY24 leading to Cash & Cash Equivalents of Rs 3,820 million as on June 30 2023. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences said, “Our performance in the quarter was driven by Generic API and the CDMO businesses. Geographically, the US, Europe, ROW and India markets spearheaded this growth. We remain focused on our strategic priorities of building capacities as well as strengthening our product pipeline. This coupled with an improved demand environment and supply situation will act as a catalyst for growth in the coming quarters.” Commenting on the company’s performance Tushar Mistry, CFO, Glenmark Life Sciences said, “I am delighted to report continued growth momentum in Q1 with improved gross margins on the back of rationalisation in input cost and improved product mix. EBITDA and PAT margins improved due to better gross margins. GLS generated strong free cash flow of Rs 98 crore during the quarter further strengthening the debt-free balance sheet.” Result PDF21-07-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q1 FY2421-07-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Management Discussion & Analysis21-07-2023
Glenmark Life Sciences Ltd - 543322 - Unaudited Financial Results For The First Quarter Ended June 30, 2023
Unaudited Financial Results for the First Quarter ended June 30, 202321-07-2023
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call Intimation14-07-2023
Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window
As per "Code of Conduct for prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its Directors'' and other designated persons regarding closure of Trading Window from June 30, 2023 to July 23, 2023 (both days inclusive) for the purpose of Unaudited Financial Results for the first quarter ended June 30, 2023.13-07-2023
Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company For The First Quarter Ended June 30, 2023.
Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the first quarter ended June 30, 2023.13-07-2023
Nirma, 3 private equity firms in race to buy Glenmark Life Sciences
Glenmark owns 82.8 per cent stake in the company which closed at a total market valuation of Rs 6,361 crore on Tuesday with its shares closing at Rs 519 a share on Tuesday23-05-2023
Glenmark Life Sciences Ltd - 543322 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Annual Secretarial Compliance Report for the financial year 2022-23.18-05-2023